Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 326

1.

Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.

Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y.

PLoS One. 2012;7(12):e52095. doi: 10.1371/journal.pone.0052095. Epub 2012 Dec 14.

2.

Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.

Qiao Z, Ren S, Li W, Wang X, He M, Guo Y, Sun L, He Y, Ge Y, Yu Q.

Biochem Biophys Res Commun. 2013 Apr 26;434(1):95-101. doi: 10.1016/j.bbrc.2013.03.059. Epub 2013 Mar 27.

PMID:
23541946
3.

A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.

Yang L, Liang Q, Shen K, Ma L, An N, Deng W, Fei Z, Liu J.

Biomed Pharmacother. 2015 Apr;71:70-8. doi: 10.1016/j.biopha.2015.02.019. Epub 2015 Feb 26.

PMID:
25960218
4.

Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression.

Tseng TH, Chien MH, Lin WL, Wen YC, Chow JM, Chen CK, Kuo TC, Lee WJ.

Environ Toxicol. 2017 Feb;32(2):434-444. doi: 10.1002/tox.22247. Epub 2016 Feb 12.

PMID:
26872304
5.

Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.

Hui KF, Cheung AK, Choi CK, Yeung PL, Middeldorp JM, Lung ML, Tsao SW, Chiang AK.

Int J Cancer. 2016 Jan 1;138(1):125-36. doi: 10.1002/ijc.29698. Epub 2015 Aug 11.

6.

Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.

Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA.

Urol Oncol. 2013 Nov;31(8):1770-9. doi: 10.1016/j.urolonc.2012.06.015. Epub 2012 Sep 1.

PMID:
22944197
7.

Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.

Thakur VS, Gupta K, Gupta S.

Carcinogenesis. 2012 Feb;33(2):377-84. doi: 10.1093/carcin/bgr277. Epub 2011 Nov 23.

8.

Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.

Zhao B, He T.

Oncol Rep. 2015 Jan;33(1):304-10. doi: 10.3892/or.2014.3595. Epub 2014 Nov 10.

PMID:
25384499
9.

Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.

Xu X, Xie C, Edwards H, Zhou H, Buck SA, Ge Y.

PLoS One. 2011 Feb 16;6(2):e17138. doi: 10.1371/journal.pone.0017138.

10.

An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.

Tinari N, De Tursi M, Grassadonia A, Zilli M, Stuppia L, Iacobelli S, Natoli C.

Curr Cancer Drug Targets. 2012 May;12(4):439-52. Review.

PMID:
22309455
11.

Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells.

Feng W, Cai D, Zhang B, Lou G, Zou X.

Biomed Pharmacother. 2015 Aug;74:257-64. doi: 10.1016/j.biopha.2015.08.017. Epub 2015 Aug 28.

PMID:
26349994
12.

FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.

Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K.

Int J Oncol. 2004 Mar;24(3):679-85.

PMID:
14767553
13.

SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.

Ryu JK, Lee WJ, Lee KH, Hwang JH, Kim YT, Yoon YB, Kim CY.

Cancer Lett. 2006 Jun 8;237(1):143-54. Epub 2005 Jul 11.

PMID:
16009488
14.

Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.

Chun SG, Zhou W, Yee NS.

Cancer Biol Ther. 2009 Jul;8(14):1328-39. Epub 2009 Jul 6.

PMID:
19421011
15.

Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.

Gaisina IN, Tueckmantel W, Ugolkov A, Shen S, Hoffen J, Dubrovskyi O, Mazar A, Schoon RA, Billadeau D, Kozikowski AP.

ChemMedChem. 2016 Jan 5;11(1):81-92. doi: 10.1002/cmdc.201500456. Epub 2015 Nov 23.

16.

HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).

Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, Bernard S, Igor S, Anabela CD, Dominique L, Eric M, Ali O.

Pancreatology. 2012 Mar-Apr;12(2):146-55. doi: 10.1016/j.pan.2012.02.013. Epub 2012 Feb 25.

PMID:
22487525
17.

Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.

Clarke JD, Hsu A, Yu Z, Dashwood RH, Ho E.

Mol Nutr Food Res. 2011 Jul;55(7):999-1009. doi: 10.1002/mnfr.201000547. Epub 2011 Mar 4.

18.

An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.

Reddy ND, Shoja MH, Biswas S, Nayak PG, Kumar N, Rao CM.

Chem Biol Interact. 2016 Jun 25;253:112-24. doi: 10.1016/j.cbi.2016.05.008. Epub 2016 May 6.

PMID:
27163855
19.
20.

A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.

Patra N, De U, Kim TH, Lee YJ, Ahn MY, Kim ND, Yoon JH, Choi WS, Moon HR, Lee BM, Kim HS.

Biomed Pharmacother. 2013 Jun;67(5):407-15. doi: 10.1016/j.biopha.2013.01.006. Epub 2013 Feb 16.

PMID:
23583193

Supplemental Content

Support Center